# GHR-2 (GHRP-2) Peptide

> GHRP-2 is a ghrelin-receptor agonist that stimulates GH release, appetite signaling, pituitary hormone response, and endocrine testing pathways.

Canonical: https://pepflow.app/peptides/ghr-2/

The Strong Pulse

A synthetic GHRP and pralmorelin-family ghrelin receptor agonist known for strong GH stimulation, appetite signaling, and diagnostic endocrine research.

GH pulse  Body composition  Recovery

Tier C

Evidence Preliminary

Safety Moderate Data

FDA status Not Approved

Last reviewed October 25, 2026 46 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is GHR-2 (GHRP-2)?

GHRP-2 is a synthetic growth hormone-releasing peptide that acts as a ghrelin/GHS receptor agonist. It stimulates pituitary GH release and is part of the older GHRP family that includes GHRP-6, GHRP-2, hexarelin, and ipamorelin.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/15230633/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

GHRP-2 is generally more potent for GH release than GHRP-6 and less selective than ipamorelin, with more cortisol and prolactin concern than the cleaner GHRP profile.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

GHRP-2 naming often overlaps with pralmorelin, KP-102, and growth hormone-releasing peptide-2. Those names point to the same ghrelin-receptor secretagogue family, but they do not make GHRP-2 interchangeable with GHRP-6, ipamorelin, or GHRH analogs.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/15230633/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) For more context, read the [GHRP-2 side-effect discussion](<https://pepflow.app/blog/ghrp-2-side-effects/>).

## What GHR-2 (GHRP-2) is investigated for

GHR-2 (GHRP-2) evidence is grouped by practical use case and injectable and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### GH release and IGF-1 response Injectable 60% Emerging

GHRP-2 is best framed as a GH secretagogue with limited long-term outcome evidence.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/19682503/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)

#### Human evidence

Human studies support GH and IGF-1 response and diagnostic testing, but not long-term fat-loss, lean-mass, sleep, recovery, or wellness outcomes.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/18493103/>)

#### Animal / mechanistic evidence

Animal and cell studies support ghrelin/GHS receptor biology and pituitary GH release.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/7606243/>) [\[34\]](<https://pubmed.ncbi.nlm.nih.gov/9688350/>)

### ### Appetite and food-intake signaling Injectable 56% Emerging

Appetite stimulation can be useful in wasting contexts or undesirable for fat-loss goals, so the same signal should not be framed as a universal benefit.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

#### Human evidence

Human studies show GHRP-2 can increase food intake in obese subjects, with effects that depend on compound, dose, and population.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

#### Animal / mechanistic evidence

Ghrelin-receptor biology directly supports appetite signaling.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

### ### Fat loss and lean mass Injectable 28% Limited

Fat-loss and lean-mass claims remain indirect GH-axis hypotheses rather than demonstrated GHRP-2 outcomes.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)

#### Human evidence

Human GH/IGF-1 response data do not establish durable fat-mass or lean-mass outcomes with GHRP-2.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>)

#### Animal / mechanistic evidence

Interest in fat-mass and lean-mass outcomes is extrapolated from GH-axis pharmacology and animal growth or tissue models.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/10793268/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/11164330/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)

### ### Training recovery Injectable 26% Limited

Training recovery should be displayed as a separate, low-confidence tissue-model claim.[\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>) [\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

#### Human evidence

Controlled human recovery endpoints, return-to-training data, and injury-repair outcomes are not established for GHRP-2.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>)

#### Animal / mechanistic evidence

A rat rotator-cuff tendon-bone healing model supports a tissue-recovery rationale, but it does not prove athlete recovery in people.[\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/20805679/>)

### ### Sleep quality Injectable 16% Insufficient

Sleep quality is a common GHRP-2 tracking claim, but current evidence supports GH-axis signaling rather than a proven sleep benefit.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)

#### Human evidence

Controlled human sleep-quality, insomnia, sleep-stage, or deep-sleep outcome trials are not established for GHRP-2.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>)

#### Animal / mechanistic evidence

The sleep rationale is indirect, based on GH-pulse physiology rather than a dedicated sleep mechanism.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>)

## Evidence snapshot

### Overall confidence

Emerging

56%

GHRP-2 has credible human GH-secretagogue data and ghrelin-receptor pharmacology. Practical confidence is limited by missing approved therapeutic use and long-term outcome trials.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

55%

### Human evidence

Emerging

Available human studies support GH and IGF-1 response, food-intake effects, diagnostic testing, and anti-doping detection. They do not establish long-term wellness outcomes.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

46%

### Animal / preclinical

Preliminary

Animal and cell studies support ghrelin/GHS receptor biology, food intake, inflammation, and tissue-model hypotheses. Those findings remain secondary to human endocrine limits.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/19682503/>) [\[28\]](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)

65%

### Mechanism support

Moderate

Ghrelin/GHS receptor activation directly explains GH release, appetite effects, and off-target endocrine monitoring. Mechanistic confidence is stronger than outcome confidence.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

## Forms & administration

GHRP-2 has short-acting injectable presentations and an investigational oral form with limited pediatric evidence. Oral preparation and weight-based amounts differ from injectable protocols; neither an adult oral product nor an interchangeable injection-to-oral dose is established.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[41\]](<https://pubmed.ncbi.nlm.nih.gov/14513874/>)

Injectable Oral

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Injectable protocols use 100-300 mcg per dose. Intranasal protocols use 100 mcg per dose.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[32\]](<https://pubmed.ncbi.nlm.nih.gov/9390009/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/26401470/>)

### Frequency

Injectable protocols use 2-3 doses daily. Intranasal protocols use 2 doses daily.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[32\]](<https://pubmed.ncbi.nlm.nih.gov/9390009/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/26401470/>)

### Timing Considerations

Common timing is morning, before a workout, or before bed, usually away from food.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[32\]](<https://pubmed.ncbi.nlm.nih.gov/9390009/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/26401470/>)

### Cycle Length

Injectable cycles run 8-12 weeks. Intranasal cycles run about 4 weeks.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[32\]](<https://pubmed.ncbi.nlm.nih.gov/9390009/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/26401470/>)

[Full GHR-2 (GHRP-2) dosage guide](<https://pepflow.app/peptides/ghr-2/dosage/>)

## What to expect

### First week

Injectable GH-pulse use may first show stronger hunger, sleep changes, water retention, or shifts in training-day recovery.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

### Weeks 4-8

Appetite pattern, waist, training tolerance, recovery notes, IGF-1, and fasting glucose become clearer once timing and food windows are consistent.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

### After stopping

Appetite, water retention, and IGF-1-related markers often drift toward baseline after short-acting GH secretagogue exposure ends.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/15230633/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

## Safety profile

Injectable GHRP-2 safety centers on appetite change, water retention, glucose and IGF-1 effects, ACTH/cortisol/prolactin biology, injection quality, pregnancy avoidance, active malignancy caution, and sports prohibition.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

### Common side effects

- Appetite change [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)
- Water retention [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

### Cautions

- Glucose monitoring[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- ACTH/cortisol/prolactin effects[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)
- Active malignancy[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- Sports prohibited[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Who GHR-2 (GHRP-2) is not for

Route-specific avoid and medical-review notes:

- **Active or recent cancer**

  Avoid outside specialist-directed care because GH/IGF-1 pathway stimulation can be inappropriate in malignancy contexts.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- **Pregnancy or breastfeeding**

  Avoid because reproductive and lactation safety are not established for unapproved GH secretagogue use.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- **Acromegaly or GH excess**

  Do not add GH secretagogue stimulation when GH/IGF-1 excess is present or suspected.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Diabetes medications**

  Diabetes medications can become harder to adjust when injectable GH-axis stimulation shifts glucose control; this is a theoretical GH/insulin-axis caution.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- **Other GH-axis agents**

  GHRH analogs, GHRPs, or HGH can add overlapping IGF-1, water-retention, glucose, and sports-risk concerns with injectable GHRP-2; this is a stack-level safety caution.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

## Pairing notes

### Not recommended with

**Somatropin: compounded GH/IGF-1 effects** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/10037246/>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>) [\[42\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**Ipamorelin: duplicate GH-release signal** Injectable, Intranasal

Ipamorelin and GHRP-2 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[\[43\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/10037246/>) [\[44\]](<https://www.fda.gov/media/182088/download>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

**GHRP-6: duplicate GH-release signal** Injectable, Intranasal

GHRP-2 and GHRP-6 both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/10037246/>) [\[45\]](<https://pubmed.ncbi.nlm.nih.gov/7952160/>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

**Hexarelin: duplicate GH-release signal** Injectable, Intranasal

GHRP-2 and Hexarelin both stimulate the ghrelin/GHS receptor pathway to release growth hormone. Combining two secretagogues duplicates the same release signal without an established additive clinical benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/10037246/>) [\[46\]](<https://pubmed.ncbi.nlm.nih.gov/8921821/>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

### Related peptides

[Ipamorelin](<https://pepflow.app/peptides/ipamorelin/>)

## Regulatory status

### United States

GHRP-2 has no FDA-approved injectable U.S. use as of 2026-06-21. FDA warning-letter materials also state GHRP-2 was not eligible for 503A exemptions in that context because it was not on the bulks list or an approved-drug component.[\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · As of 2026-06-21, GHRP-2 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval.[\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>) | Not Listed · FDA warning-letter materials state that GHRP-2 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it.[\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>) |

### Injectable

FDA drug approval

Not Approved

As of 2026-06-21, GHRP-2 was not FDA-approved as an injectable drug. FDA warning-letter context also separates 503A eligibility from FDA drug approval.[\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

503A compounding

Not Listed

FDA warning-letter materials state that GHRP-2 did not appear on the 503A Bulks List, was not an FDA-approved drug component, and had not been nominated with adequate support for FDA to evaluate it.[\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

### International

EU/Europe, UK, Canada, and Australia should be checked by local medicine and compounding rules; any non-U.S. diagnostic or research context should not be generalized to therapeutic approval.

### Sports & competition

WADA's 2026 Prohibited List treats GHRPs and growth hormone secretagogues as S2-prohibited; tested athletes should treat injectable GHRP-2 use as prohibited without a valid TUE.[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

GHRP-2 is a ghrelin/GHS receptor agonist that triggers pituitary GH release rather than acting as replacement growth hormone. Human endocrine studies show GH and IGF-1 responses, and a separate appetite study shows that ghrelin-receptor signaling can affect food intake.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

For injectable use, that broader receptor biology matters because GHRP-2 is less selective than cleaner GH-secretagogue narratives suggest. The mechanism can overlap with appetite, glucose, fluid retention, cortisol, and prolactin interpretation; it does not prove long-term body-composition, recovery, sleep, or longevity benefit in people.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/20045717/>)

## Research gaps & open questions

What the current literature has not yet settled about GHR-2 (GHRP-2):

01

Long-term controlled studies need to show whether GHRP-2 improves fat loss, lean mass, recovery, or sleep, and how repeated use affects blood sugar, IGF-1, cortisol, and prolactin.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

02

Direct comparisons with other growth-hormone-releasing peptides should measure real benefits and side effects, not only the size of a temporary growth-hormone pulse.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

03

Athletes need clearer data on detection windows and product-contamination risk because GHRP-2 is prohibited in sport.[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Common questions

### Is GHRP-2 FDA-approved?

No. GHRP-2 has no FDA-approved injectable U.S. use, and it is not on the 503A Bulks List.[\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

### Is GHRP-2 banned in tested sports?

Yes. WADA treats GHRPs and GH secretagogues such as GHRP-2 as S2-prohibited without a valid TUE.[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### What makes GHRP-2 different?

GHRP-2 is generally more potent for GH release than GHRP-6 and less selective than ipamorelin, with more cortisol, prolactin, and appetite concern.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

## Myths & misconceptions

### Myth

GHRP-2 is undetectable because it clears quickly.

### Reality

Short plasma exposure does not mean no sports-detection risk; WADA class rules and urine metabolite methods matter.[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/20552695/>)

### Myth

GHRP-2 is safe because it stimulates natural GH.

### Reality

Stimulating endogenous GH is still pharmacologic and can affect appetite, glucose, water retention, IGF-1, cortisol, or prolactin depending on the compound.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

## History & discovery

GHRP-2, also known as pralmorelin, belongs to the synthetic secretagogue lineage that helped separate ghrelin/GHS-receptor pharmacology from direct growth hormone replacement.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/15230633/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

Phase I and older-adult studies used GHRP-2 to probe GH and IGF-1 responses, often alongside GHRH, before wellness-market protocols became common.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11322505/>) [\[33\]](<https://pubmed.ncbi.nlm.nih.gov/9543135/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

Human obesity research showed GHRP-2 could stimulate food intake, helping connect the peptide with ghrelin-like appetite signaling as well as GH release.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)

Urine detection work and WADA class rules made anti-doping status part of the modern history, while U.S. use remains outside FDA-approved injectable products.[\[40\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/20552695/>) [\[35\]](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>) [\[38\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)

## Published research 46 citations

- [\[1\] **Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.** European journal of endocrinology, 1999 Jan. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10037246/>)
- [\[2\] **Preservation of growth hormone secretion in response to growth hormone-releasing peptide-2 during prednisone therapy.** Metabolism: clinical and experimental, 1999 May. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10337858/>)
- [\[3\] **The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine.** Domestic animal endocrinology, 2000 Apr. animal.](<https://pubmed.ncbi.nlm.nih.gov/10793268/>)
- [\[4\] **Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine.** Domestic animal endocrinology, 2001 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/11164330/>)
- [\[5\] **Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.** Endocrine, 2001 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/11322501/>)
- [\[6\] **Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.** Endocrine, 2001 Feb. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/11322505/>)
- [\[7\] **Chicken ghrelin and growth hormone-releasing peptide-2 inhibit food intake of neonatal chicks.** European journal of pharmacology, 2002 Oct 18. animal.](<https://pubmed.ncbi.nlm.nih.gov/12393062/>)
- [\[8\] **Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.** Drugs in R&D, 2004. review.](<https://pubmed.ncbi.nlm.nih.gov/15230633/>)
- [\[9\] **Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.** Obesity (Silver Spring, Md.), 2006 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16861611/>)
- [\[10\] **Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism.** Endocrine journal, 2008 Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/18493103/>)
- [\[11\] **The effect of growth hormone releasing peptide-2 on upper gastrointestinal contractile activity and food intake in conscious dogs.** Journal of gastroenterology, 2009. animal.](<https://pubmed.ncbi.nlm.nih.gov/19271111/>)
- [\[12\] **Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary.** Regulatory peptides, 2009 Nov 27. animal.](<https://pubmed.ncbi.nlm.nih.gov/19682503/>)
- [\[13\] **Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report.** Neurologia medico-chirurgica, 2009 Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/19707004/>)
- [\[14\] **Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study.** Peptides, 2010 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/20045717/>)
- [\[15\] **Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.** Endocrine journal, 2010. review.](<https://pubmed.ncbi.nlm.nih.gov/20431231/>)
- [\[16\] **Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry.** Rapid communications in mass spectrometry : RCM, 2010 Jul 30. review.](<https://pubmed.ncbi.nlm.nih.gov/20552695/>)
- [\[17\] **Growth hormone releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats.** The Tohoku journal of experimental medicine, 2010 Sep. animal.](<https://pubmed.ncbi.nlm.nih.gov/20805679/>)
- [\[18\] **Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement.** Drug testing and analysis, 2010 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/20878896/>)
- [\[19\] **Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects.** Drug testing and analysis, 2010 Nov-Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/21249726/>)
- [\[20\] **Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice.** Clinics (Sao Paulo, Brazil), 2012. animal.](<https://pubmed.ncbi.nlm.nih.gov/22473409/>)
- [\[21\] **Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity.** AAPS PharmSciTech, 2015 Oct. review.](<https://pubmed.ncbi.nlm.nih.gov/25761386/>)
- [\[22\] **One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient.** Journal of cachexia, sarcopenia and muscle, 2015 Sep. review.](<https://pubmed.ncbi.nlm.nih.gov/26401470/>)
- [\[23\] **Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure.** Endocrine journal, 2016 Jun 30. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/27020037/>)
- [\[24\] **Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.** International journal of molecular sciences, 2016 Aug 19. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/27548147/>)
- [\[25\] **Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas.** Endocrine journal, 2018 Oct 29. review.](<https://pubmed.ncbi.nlm.nih.gov/29973439/>)
- [\[26\] **Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.** Journal of the Endocrine Society, 2022 Aug 1. review.](<https://pubmed.ncbi.nlm.nih.gov/35795807/>)
- [\[27\] **Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly.** Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2023 Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/37295337/>)
- [\[28\] **Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model.** Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025 Jul. animal.](<https://pubmed.ncbi.nlm.nih.gov/39672241/>)
- [\[29\] **Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.** The Journal of clinical endocrinology and metabolism, 1995 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7559885/>)
- [\[30\] **Effects of growth hormone-releasing peptide-2 (GHRP-2) on membrane Ca2+ permeability in cultured ovine somatotrophs.** Journal of neuroendocrinology, 1995 Mar. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/7606243/>)
- [\[31\] **Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves.** Endocrine journal, 1996 Jun. animal.](<https://pubmed.ncbi.nlm.nih.gov/8886623/>)
- [\[32\] **Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.** The Journal of endocrinology, 1997 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9390009/>)
- [\[33\] **Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.** The Journal of clinical endocrinology and metabolism, 1998 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9543135/>)
- [\[34\] **Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours.** Journal of neuroendocrinology, 1998 Jun. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/9688350/>)
- [\[35\] **Drugs@FDA/openFDA query for GHRP-2** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22GHRP-2%22&limit=1>)
- [\[36\] **Drugs@FDA/openFDA query for Pralmorelin** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Pralmorelin%22&limit=1>)
- [\[37\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[38\] **United Pharmacy MARCS-CMS 553916 - February 11, 2019** U.S. Food and Drug Administration, 2019-02-11. regulatory.](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- [\[39\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[40\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[41\] **Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.** Journal of pediatric endocrinology & metabolism : JPEM, 2003 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/14513874/>)
- [\[42\] **NORDITROPIN somatropin injection prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)
- [\[43\] **Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.** Pharmaceutical research, 1999 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)
- [\[44\] **October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document 4 - Ipamorelin** U.S. Food and Drug Administration, 2024-10-29. regulatory.](<https://www.fda.gov/media/182088/download>)
- [\[45\] **Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging** European Journal of Endocrinology, 1994-11. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7952160/>)
- [\[46\] **Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.** European Journal of Endocrinology, 1996 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8921821/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

C

**Evidence**

56% Preliminary

**Safety**

Moderate Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[46 citations](<https://pepflow.app/peptides/ghr-2/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- GH release and IGF-1 response
- Appetite and food-intake signaling
- Fat loss and lean mass
- Training recovery
- Sleep quality

### Common side effects

- Appetite change
- Water retention

### Also known as

- GHRP-2
- Growth Hormone Releasing Peptide-2
- Pralmorelin
- KP-102

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Know Ghrp 2 Side Effects: Safe Use & Mitigation](<https://pepflow.app/blog/ghrp-2-side-effects/>)
- [GHR-2 (GHRP-2) dosage guide](<https://pepflow.app/peptides/ghr-2/dosage/>)
- [Ipamorelin Peptide](<https://pepflow.app/peptides/ipamorelin/>)
